Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease

21Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient-reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to present symptoms that influence QoL. Identification of these symptoms during treatment can lead to earlier symptom management and thus secure improvements in QoL. Methods: BC patients in chemo- or immunotherapy for locally advanced or metastatic disease reported weekly PROs for the duration of their treatment. The PROs included EORTC QLQ-C30 and QLQ-BLM30 and 45 selected PRO-CTCAE items. Spearman's correlation analysis was performed for all PRO-CTCAE items and QLQ-C30 global QoL and subdomains. Results: In this study, 78 BC patients reported 724 questionnaires. Spearman's analysis showed significant correlations between almost all PRO-CTCAE items and the expected domain of QoL. The PRO-CTCAE items with the strongest correlations with QoL were anxiety (F, frequency item) and emotional function (rs = −0.603, P '.0001), concentration (S, severity item) and cognitive function (rs = −0.704, P '.0001), discouraged (F) and emotional function (rs = −0.659, P '.0001), fatigue (S) and role function (rs = −0.659, P '.0001) and sad (F) and emotional function (rs = −0.711, P '.0001). The weakest correlations were found for the PRO-CTCAE items urinary frequency, incontinence and urge, all with variations in the direction and significance of the correlations. Conclusions: This study delivers information on which PROs may influence QoL for patients in clinical trials or daily clinic. Psychological issues have a strong impact on QoL and should be dealt with during treatment to secure the best possible QoL for BC patients.

References Powered by Scopus

Pembrolizumab as second-line therapy for advanced urothelial carcinoma

2772Citations
N/AReaders
Get full text

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

2313Citations
N/AReaders
Get full text

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study

2100Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma

37Citations
N/AReaders
Get full text

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

23Citations
N/AReaders
Get full text

Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review

18Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Taarnhøj, G. A., Johansen, C., Lindberg, H., Basch, E., Dueck, A., & Pappot, H. (2020). Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Medicine, 9(9), 3078–3087. https://doi.org/10.1002/cam4.2958

Readers over time

‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

59%

Researcher 6

35%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

43%

Nursing and Health Professions 5

36%

Biochemistry, Genetics and Molecular Bi... 2

14%

Pharmacology, Toxicology and Pharmaceut... 1

7%

Save time finding and organizing research with Mendeley

Sign up for free
0